A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Novartis Pharmaceuticals Corporation
The purpose of this part of the study is to evaluate safety of Lutathera in patients with extensive stage small cell lung cancer (ES-SCLC) and to find the recommended dose of Lutathera in combination with carboplatin, etoposide and atezolizumab. The use of Lutathera in combination with carboplatin, etoposide and atezolizumab for ES-SCLS is considered as experimental and not approved by U.S. Food and Drug Administration.
Enrollment Form
This study is currently enrolling.